Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites

NCT02400164 · View on ClinicalTrials.gov ↗

Study Summary

The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites. Patients will be enrolled during a 6 month enrollment phase after which data will be collected for 12months with an initial analysis after 3 months. Extended follow-up for safety monitoring purposes will continue for the lifetime of the patient or until the device is explanted.

Conditions Studied

Interventions

  • DEVICE alfapump system

Study Locations (6)

Virginia

  • University of Virginia — Charlottesville
  • VCU Medical Centre — Richmond

California

  • California Pacific Medical — San Francisco

Minnesota

  • Mayo Clinic — Rochester

Texas

  • Baylor University Healthcare System — Dallas

Ontario

  • Toronto General Hospital — Toronto

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-03
Est. Completion 2018-03-31
Phase NA

Sponsor

Sequana Medical N.V.

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02400164

The ClinicalTrials.gov registry entry for NCT02400164 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sequana Medical N.V., which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention — of which alfapump system is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02400164 reports 6 study locations spanning 5 distinct geographic areas — top geographies include Virginia, California, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02400164 about?

NCT02400164 is a clinical study titled "A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites". The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites. Patients will be enrolled during a 6 month enrollment phase after which data will be collected for 12months with an initial ...

What is the current status of trial NCT02400164?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-03. Estimated completion is 2018-03-31.

What conditions does trial NCT02400164 study?

This clinical trial studies the following conditions: Cirrhosis, Ascites. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02400164?

The interventions under investigation include: alfapump system (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02400164?

This trial is sponsored by Sequana Medical N.V., which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02400164 being conducted?

This trial has 6 study locations across California, Minnesota, Texas, Virginia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial